| For Safety, NHLBI Changes Intensive Blood Sugar Treatment
Strategy in Clinical Trial of Diabetes and Cardiovascular Disease The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health has stopped one treatment within a large, ongoing North American clinical trial of diabetes and cardiovascular disease 18 months early due to safety concerns after review of available data, although the study will continue. In this trial of adults with type 2 diabetes at especially high risk for heart attack and stroke, the medical strategy to intensively lower blood glucose (sugar) below current recommendations increased the risk of death compared with a less-intensive standard treatment strategy. Study participants receiving intensive blood glucose lowering treatment will now receive the less-intensive standard treatment. |
| Comunicato stampa da parte del National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health |
|
Resources:
|